Better biologics for the toughest targets.

Keep scrolling

Announcement
Series A closed at $9.3M · Research agreement with the Cystic Fibrosis Foundation

DeDe novonovo antibodyantibody discoverydiscovery forfor GPCRsGPCRs andand challengingchallenging targets.targets. DesignedDesigned withwith GenerativeGenerative AI.AI.

The Data Advantage

AA decadedecade ofof pioneeringpioneering biologicsbiologics forfor thethe hardesthardest drugdrug discoverydiscovery targetstargets inin medicine.medicine.

Pioneers

Data Moat

Experience

Our models are built on specialized GPCR data, capturing structural features and complexities that broad protein models can overlook.

10 Years

Training data purpose built for GPCRs and transmembrane proteins, since 2017.

2000x

Greater hit rate vs naive library, in the discovery of functional agonist antibodies for a Class A GPCR.

>240

Proprietary stable cell lines for GPCRs and ion channels, which exponentially increase true binder discovery rates.

The advantage

LeadingLeading AI-poweredAI-powered discoverydiscovery  ofof functional,functional, developabledevelopable biologicsbiologics forfor thethe mostmost challengingchallenging targets.targets.

Generative De Novo Design
Novel chemical space, sequence or structure based.
Diverse antibody formats
Any biologic format with a heavy chain (mAbs, VHH/VH-VL, etc.)
High success rates
2000x greater hit rates vs naive libraries.
Accelerated lead generation
Intergrated dry and wet lab enables an iterative feedback loop.
Faster generative cycles
Prioritized clones maintain their natural conformation, enabling characterization in 1 month.

Generative De Novo Design
Novel chemical space, sequence or structure based.
Diverse antibody formats
Any biologic format with a heavy chain (mAbs, VHH/VH-VL, etc.)
High success rates
2000x greater hit rates vs naive libraries.
Accelerated lead generation
Intergrated dry and wet lab enables an iterative feedback loop.
Faster generative cycles
Prioritized clones maintain their natural conformation, enabling characterization in 1 month.

More about the Antiverse Platform

SuccessfulSuccessful partnershipspartnerships withwith leadingleading pharmapharma companiescompanies andand organizations.organizations.

Better biologics for the toughest targets.

The Data Advantage

The advantage

Generative De Novo Design

Diverse antibody formats

High success rates

Accelerated lead generation

Faster generative cycles

Generative De Novo Design

Diverse antibody formats

High success rates

Accelerated lead generation

Faster generative cycles

Trusted by